Why is the CSL (ASX:CSL) share price trading around its COVID lows?

The CSL share price is currently trading close to its March lows. Let's take a look at what's been impacting the biotech giant's shares.

| More on:
falling healthcare asx share price Mesoblast capital raising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In recent weeks, the CSL Limited (ASX: CSL) share price has been struggling to gain momentum and put its COVID-19 lows firmly behind it. Shares in the biotech giant have again been dropping today and are currently trading 0.45% lower in morning trade. This takes the CSL share price down to $275.37 – its lowest level since early August and a mere 1.6% higher than its March lows.

What's gone wrong for the CSL share price?

The CSL share price has been suffering as string of negative news has plagued the company since the release of its annual report in September. Compounding this, the lack of any particularly positive updates is also arguably playing a part in the stagnation of CSL shares.

In early December the biotech giant announced that its University of Queensland COVID-19 vaccine was to be scrapped. This came after Phase 1 trial data delivered what could be construed as misleading results regarding HIV diagnoses.

While there were no serious adverse effects or safety concerns surrounding the vaccine, it was discovered it had the potential to produce false-positive HIV test results. This was due to the molecular clamp component of the vaccine. Thus, in spite of showing potential for successfully fighting COVID-19, CSL made the decision together with the Australian Government not to continue with the vaccine's development. 

Investors were clearly unsettled by the news, as was evidenced by the 9% fall in the CSL share price following the announcement.

Pandemic hits plasma collections

In addition to terminating its COVID-19 vaccine trial, CSL has also been impacted by a decline in its plasma collections during 2020, as reported by The Wall Street Journal (WSJ). Plasma is an essential ingredient in some of CSL's immunoglobulin products and pandemic-related lockdowns have made the collection process more complicated. Almost half of CSL's sales come from these immunoglobulin products. 

CSL Chief Executive Paul Perreault said of immunoglobulin (quoted by WSJ):

Across the globe, there's going to be a lot of tightness in the market and there will be some shortages in various countries.

Whether the U.S. sees all of that or not, it really depends on how quickly plasma collections come back.

Despite the rollout of a COVID-19 vaccine having already commenced in the US, as also reported by The Wall Street Journal, the country is continuing to see record numbers of new cases, deaths and hospitalisations. 

Foolish takeaway

Despite its lacklustre returns of late, the performance of the CSL share price over the past year is not far behind that of the overall market. For perspective, the S&P/ASX 200 Index (ASX: XJO) has fallen 1.2% over the last twelve months whilst CSL shares have declined 3.67%.

In its 2020 annual report released on 4 September, CSL advised it expected strong demand from its recombinant therapies to continue, highlighting its differentiated products and strong demand for its influenza vaccines.

In the same report, the company estimated net profit after tax of approximately US$2.170 billion to US$2.265 billion for FY21.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Man standing on rock next to turquoise salt lagoon.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 finally had a green session this hump day.

Read more »

gaming asx share price rise represented by slot machine paying jackpot
Broker Notes

What does Macquarie expect from Aristocrat Leisure shares when it reports on 14 May?

Here's what the broker is expecting from this gaming technology company next week.

Read more »

Man pointing at a blue rising share price graph.
Share Gainers

Guess which ASX 300 stock just rocketed 17%!

Investors are sending the ASX 300 stock soaring higher on Wednesday. But why?

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Aurizon, JB Hi-FI, Nuix, and Platinum shares are tumbling today

These shares are falling on hump day. But why?

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Firefly, Kelsian, NAB, and Zip shares are roaring higher today

These shares are having a good time on hump day. Let's find out why.

Read more »

A man and woman sit at a desk staring intently at a laptop screen with papers next to them.
Opinions

Where I'd invest $5,000 in ASX 300 shares right now

These stocks look like excellent investments today.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Goldman Sachs says these ASX 200 stocks are strong buys

The broker is feeling very bullish about these stocks. But why?

Read more »